Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Acromegaly
/ blood
Adenoma
/ blood
Adult
Aged
Cohort Studies
Female
Growth Hormone-Secreting Pituitary Adenoma
/ blood
Human Growth Hormone
/ blood
Humans
Insulin-Like Growth Factor I
/ analysis
Magnetic Resonance Imaging
Male
Middle Aged
Neuroimaging
Predictive Value of Tests
Preoperative Period
Prognosis
ROC Curve
Reference Values
Retrospective Studies
Treatment Outcome
IGF- I
acromegaly
growth hormone
hormonal remission
transsphenoidal resection
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
07
2021
accepted:
30
09
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
25
2
2022
Statut:
epublish
Résumé
Determine predictive factors for long-term remission of acromegaly after transsphenoidal resection of growth hormone (GH)-secreting pituitary adenomas. We identified 94 patients who had undergone transsphenoidal resection of GH-secreting pituitary adenomas for treatment of acromegaly at the USC Pituitary Center from 1999-2019 to determine the predictive value of postoperative endocrine lab values. Patients underwent direct endoscopic endonasal (60%), microscopic transsphenoidal (38%), and extended endoscopic approaches (2%). The cohort was 63% female and 37% male, with average age of 48.9 years. Patients presented with acral enlargement (72, 77%), macroglossia (40, 43%), excessive sweating (39, 42%), prognathism (38, 40%) and frontal bossing (35, 37%). Seventy-five (80%) were macroadenomas and 19 (20%) were microadenomas. Cavernous sinus invasion was present in 45%. Available immunohistochemical data demonstrated GH staining in 88 (94%) and prolactin in 44 (47%). Available postoperative MRI demonstrated gross total resection in 63% of patients and subtotal resection in 37%. Most patients (66%) exhibited hormonal remission at 12 weeks postoperatively. Receiver operating characteristic (ROC) curves demonstrated postoperative day 1 (POD1) GH levels ≥1.55ng/mL predicted failure to remit from surgical resection alone (59% specificity, 75% sensitivity). A second ROC curve showed decrease in corrected insulin-like growth factor-1 (IGF-1) levels of at least 37% prognosticated biochemical control (90% sensitivity, 80% specificity). POD1 GH and short-term postoperative IGF-1 levels can be used to successfully predict immediate and long-term hormonal remission respectively. A POD1 GH cutoff can identify patients likely to require adjuvant therapy to emphasize clinical follow-up.
Identifiants
pubmed: 34867787
doi: 10.3389/fendo.2021.743052
pmc: PMC8637049
doi:
Substances chimiques
IGF1 protein, human
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
743052Informations de copyright
Copyright © 2021 Cardinal, Collet, Wedemeyer, Singer, Weiss, Zada and Carmichael.
Déclaration de conflit d'intérêts
JC: Recordati: Honoraria, advisory board Chiasma Principal investigator Crinetics Principal investigator. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pituitary. 2014 Apr;17(2):103-8
pubmed: 23475513
J Neurooncol. 2021 Jan;151(2):313-324
pubmed: 33394265
Pituitary. 2021 Feb;24(1):53-61
pubmed: 33025547
N Engl J Med. 1990 Apr 5;322(14):966-77
pubmed: 2179724
J Endocrinol Invest. 2021 Nov;44(11):2427-2433
pubmed: 33837920
Endocrine. 2020 Apr;68(1):182-191
pubmed: 32078118
J Clin Endocrinol Metab. 2013 Aug;98(8):3190-8
pubmed: 23737543
Endocrine. 2018 Jun;60(3):415-422
pubmed: 29626274
Turk Neurosurg. 2014;24(6):906-12
pubmed: 25448208
J Clin Endocrinol Metab. 2011 Sep;96(9):2732-40
pubmed: 21715544
Clin Endocrinol (Oxf). 2013 Feb;78(2):263-70
pubmed: 22783815
J Clin Endocrinol Metab. 2005 Dec;90(12):6480-9
pubmed: 16159936
Neurosurg Focus. 2020 Jun;48(6):E10
pubmed: 32480366
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
J Neurosurg. 2010 Apr;112(4):736-43
pubmed: 19835472
Pituitary. 2017 Feb;20(1):46-62
pubmed: 28224405
Pituitary. 2018 Jun;21(3):310-322
pubmed: 29605877
Neurol India. 2016 Mar-Apr;64(2):252-8
pubmed: 26954802
Clin Neurol Neurosurg. 2014 Nov;126:190-5
pubmed: 25278017
Neurosurgery. 2012 May;70(5):1106-13; discussion 1113
pubmed: 22067418
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
Acta Neurochir (Wien). 2014 Jul;156(7):1379-87; discussion 1387
pubmed: 24781680
J Neurosurg. 1998 Sep;89(3):353-8
pubmed: 9724106
Pituitary. 2020 Oct;23(5):582-594
pubmed: 32602066
J Endocrinol Invest. 2021 Jan;44(1):183-193
pubmed: 32441006
Eur J Endocrinol. 2008 Aug;159(2):89-95
pubmed: 18524797
J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8
pubmed: 20410227
Neurosurg Focus. 2010 Oct;29(4):E6
pubmed: 20887131
J Neurosurg. 2013 Dec;119(6):1467-77
pubmed: 24074496
J Neurosurg. 2019 Oct 11;:1-11
pubmed: 31604330